Bayesian Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Bayesian Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,485	Closed	-$270K	–	228
2026 Q1	$270K	Buy	+19,485	New	+$310K	0.33%	99
2025 Q4	–	Sell	-17,658	Closed	-$264K	–	119
2025 Q3	$264K	Buy	+17,658	New	+$215K	0.05%	406
2023 Q4	–	Sell	-19,239	Closed	-$105K	–	712
2023 Q3	$105K	Buy	+19,239	New	+$127K	0.01%	600
2023 Q2	–	Sell	-12,270	Closed	-$108K	–	756
2023 Q1	$108K	Buy	+12,270	New	+$108K	0.01%	679
2022 Q3	–	Sell	-21,475	Closed	-$174K	–	671
2022 Q2	$174K	Buy	+21,475	New	+$189K	0.03%	638

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bayesian Capital Management's ADPT Position: Q2 2026 in Review

Bayesian Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 19,485 shares — an estimated $270K sold.

Bayesian Capital Management first reported a position in ADPT in Q2 2022 and held it in 5 quarters. The position peaked at $270K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Bayesian Capital Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
Bayesian Capital Management sold 19,485 Adaptive Biotechnologies shares in Q2 2026, an estimated $270K.
Bayesian Capital Management first reported a position in Adaptive Biotechnologies in Q2 2022 and held it in 5 quarters.
Bayesian Capital Management's Adaptive Biotechnologies position peaked at $270K in Q1 2026.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.